tetano
Editor, Senior Moderator
Trends Immunol
. 2020 Sep 17;S1471-4906(20)30211-8.
doi: 10.1016/j.it.2020.09.004. Online ahead of print.
Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
Edem Gavor[SUP] 1 [/SUP], Yeu Khai Choong[SUP] 1 [/SUP], Shi Yin Er[SUP] 1 [/SUP], Hariharan Sivaraman[SUP] 1 [/SUP], J Sivaraman[SUP] 2 [/SUP]
Affiliations
Abstract
The 2019 coronavirus pandemic remains a major public health concern. Neutralizing antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, and discuss current progress in antibody research against rampant SARS-CoV-2 infections. We provide a perspective on the mechanisms of SARS-CoV-2-derived nAbs, comparing these with existing SARS-CoV-derived antibodies. We offer insight into how these antibodies cross-react and cross-neutralize by analyzing available structures of spike (S) glycoprotein-antibody complexes. We also propose ways of adopting antibody-based strategies - such as cocktail antibody therapeutics against SARS-CoV-2 - to overcome the possible resistance of currently identified mutants and mitigate possible antibody-dependent enhancement (ADE) pathologies. This review provides a platform for the progression of antibody and vaccine design against SARS-CoV-2, and possibly against future coronavirus pandemics.
Keywords: COVID-19; S glycoprotein; SARS-CoV; SARS-CoV-2; antibodies; hACE-2.
. 2020 Sep 17;S1471-4906(20)30211-8.
doi: 10.1016/j.it.2020.09.004. Online ahead of print.
Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
Edem Gavor[SUP] 1 [/SUP], Yeu Khai Choong[SUP] 1 [/SUP], Shi Yin Er[SUP] 1 [/SUP], Hariharan Sivaraman[SUP] 1 [/SUP], J Sivaraman[SUP] 2 [/SUP]
Affiliations
- PMID: 33041212
- DOI: 10.1016/j.it.2020.09.004
Abstract
The 2019 coronavirus pandemic remains a major public health concern. Neutralizing antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, and discuss current progress in antibody research against rampant SARS-CoV-2 infections. We provide a perspective on the mechanisms of SARS-CoV-2-derived nAbs, comparing these with existing SARS-CoV-derived antibodies. We offer insight into how these antibodies cross-react and cross-neutralize by analyzing available structures of spike (S) glycoprotein-antibody complexes. We also propose ways of adopting antibody-based strategies - such as cocktail antibody therapeutics against SARS-CoV-2 - to overcome the possible resistance of currently identified mutants and mitigate possible antibody-dependent enhancement (ADE) pathologies. This review provides a platform for the progression of antibody and vaccine design against SARS-CoV-2, and possibly against future coronavirus pandemics.
Keywords: COVID-19; S glycoprotein; SARS-CoV; SARS-CoV-2; antibodies; hACE-2.